Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


HHS Advances Payment Model to Lower Drug Costs


 

In late October, the U.S. Department of Health and Human Services, through the Centers for Medicare & Medicaid Services (CMS), announced and sought input on a new "International Pricing Index" (IPI) payment model to reduce what Americans pay for prescription drugs.

Under the IPI model, described in an Advance Notice of Proposed Rulemaking (ANPRM), Medicare's payments for select physician-administered drugs would shift to a level more closely aligned with prices in other countries. Overall savings for American taxpayers and patients are projected to total $17.2 billion over five years.

"In an era where the pharmaceutical industry is pricing drugs at levels approaching a million dollars -- and jeopardizing the future of our safety net programs -- the time has come to fix the perverse incentives in the Medicare program that are fueling price increases," said CMS Administrator Seema Verma.

The move from current payment levels to payment levels based on international prices would be phased in over a five-year period, would apply to 50 percent of the country, and would cover most drugs in Medicare Part B, which includes physician-administered medicines such as infusions. The model purports to "correct existing incentives to prescribe higher-priced drugs and, for the first time, address disparities in prices between the United States and other countries." Since patient cost sharing is calculated based on Medicare's payment amount, patients should see lower costs under the model.

For the first time in Medicare, the IPI model would create a system in which private vendors procure drugs, distribute them to physicians and hospitals, and take on the responsibility of billing Medicare. The plan is that vendors would aggregate purchasing, seek volume-based discounts, and compete for providers' business, thereby creating competition where none exists today. Under the model, instead of the current percentage-based add-on payment, physicians and hospitals would receive a set payment amount for storing and handling drugs that would not be tied to drug prices to remove any financial incentive to prescribe higher-cost drugs.

AMA President Barbara L. McAneny, MD, responded to the proposed rule with the following statement: "Physicians share their patients' concerns with the high cost of prescription drugs. We appreciate that the Trump Administration is working to address this important issue. The Administration's proposal for an International Pricing Index Model for Part B drugs raises a number of questions, and we need to have a greater understanding of the potential impact of the proposal on patients, physicians, and the health care system. We look forward to working constructively with the Administration as it seeks feedback."

TAGS:

WEB:

IPI Policy Brief

Fact Sheet

Comments

 
Share:

Related Articles:


Recent Articles

AMA Issues Checklist for the Transition to E/M Office Visit Changes

The American Medical Association (AMA) is helping physician practices integrate fundamental changes to the coding and documentation of evaluation and management (E/M) office visit services that account for nearly $23 billion in Medicare spending.

Read More

AHA's Maryjane Wurth To Retire In 2020; Michelle Hood To Join The Association

Maryjane Wurth, the American Hospital Association's (AHA) executive vice president and chief operating officer (COO), will retire next year after a long and distinguished career in the hospital association field.

Read More

Tennessee Sees Fewer Infant Deaths In 2018

Infant Mortality Data Dashboard Now Available

Read More

Amedisys Expanding Commitment to End-of-Life Care for Veterans

Third Largest Hospice Provider Cared for 5,540 Dying Veterans Last Year

Read More

AMA Applauds Relief from Documentation Burden in New Medicare Rule

Many physicians will have reduced documentation beginning in 2021

Read More

Oncology Innovation in Nashville

From personalized medicine to innovation in GI care, Middle Tennessee oncology leaders share promising news.

Read More

Critical Insights into Nashville Health

For the first time in nearly two decades, Nashville has a countywide assessment providing insights into the health and well-being of the community.

Read More

Physician Spotlight: Leading with Compassion

Hospice care is so much more than simply pain management. Compassus CMO Dr. Kurt Merkelz focuses on helping patients live fully until the end.

Read More

The Oncology Care Model Value Proposition

The American Journal of Managed Care® hosts meetings across the country to help oncology practices understand and navigate the value-based care landscape at the intersection of quality and efficiency.

Read More

Tennessee Falling Short on Cancer-Fighting Public Policies

A 2019 ACS CAN report shows the state is falling short on public policies to fight cancer.

Read More

Email Print
 
 

 

 


Tags:
CMS, HHS, International Pricing Index, IPI, Medicare, Medicare Part B, Prescription Drugs, Seema Verma
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: